[Aflibercept for age-related macular degeneration and central retinal vein occlusion]
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Romano M
Record ID 32014000267
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage policy related aspects on the use of aflibercept in patients with age-related macular degeneration and central retinal artery thrombosis.
Authors' recommendations:
The evidence found for wet AMD was of very high methodological quality. All the aflibercept doses and schemes evaluated were as effective as ranibizumab (standard treatment) for the treatment of wet AMD patients. No evidence was found supporting aflibercept in patients with central retinal vein occlusion.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1534&origen_publicacion=publicaciones
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Receptors, Vascular Endothelial Growth Factor
- Angiogenesis Inhibitors
- Macular Degeneration
- Retinal Vein Occlusion
- Recombinant Fusion Proteins
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.